千金药业(600479.SH)：重组事项将于8月18日上会

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) plans to acquire 28.92% equity of Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68.00% equity of Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through a combination of share issuance and cash payment [1] Group 1 - The acquisition is subject to review by the Shanghai Stock Exchange's M&A Reorganization Review Committee, which is scheduled to meet on August 18, 2025, to assess the company's application for this transaction [1]